This site is intended for healthcare professionals
Drug news

Trial comparing Xience V (Abbott) with Endeavor Resolute (Metronic) shows non-inferiority for PCI patients

Read time: 1 mins
Last updated:16th Nov 2011
Published:16th Nov 2011
Source: Pharmawand
The TWENTE clinical trial, which compared two second generation drug-eluting stents � the Endeavor Resolute zotarolimus stent from Medtronic and the Xience V everolimus-eluting stent from Abbott � established non-inferiority between the two stents as measured by the primary endpoint: target vessel failure (TVF) at one year. Both stents also demonstrated low rates of stent thrombosis. TVF at one year occurred in 8.2% of patients for the zotarolimus-eluting stent, and in 8.1% of patients for the everolimus-eluting stent (p=0.94). For the components of the primary endpoint, there were also no significant differences: cardiac death (1.0% vs. 1.4%, p=0.46), target vessel-related myocardial infarction (4.6% vs. 4.6%, p=0.98), and clinically driven target vessel revascularization (3.3% vs. 2.7%, p=0.53). TWENTE showed similar and � considering the complexity of the patient population and the lesion characteristics � relatively low one-year rates of definite-plus-probable stent thrombosis for the zotarolimus and everolimus-eluting stents (0.86% and 1.16%, respectively). TWENTE also showed a low definite one-year stent thrombosis rate for zotarolimus and everolimus-eluting stents (0.58% and 0%, respectively). Zotarolimus-eluting stents are non-inferior to everolimus-eluting stents in terms of safety and efficacy for treating 'real-world' patients with a vast majority of complex lesions and 'off-label' indications, according to lead researcher Clemens von Birgelen, Professor of Cardiology at University of Twente in the Netherlands. Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.